URGN UroGen Pharma Ltd
P/E
--
Forward P/E
12.9
Price/Sales
4.963
Beta
1.637
Div Yield
--
Market Cap
--
Company Analysis
Latest News
UroGen Pharma Files FDA Application for UGN-103, Citing 77.8% Response Rate
UroGen Pharma submitted a New Drug Application (NDA) to the FDA for its investigational drug, UGN-103. This mitomycin-based formulation treats adults with...
🟢 UroGen Pharma is trading 4.25% up today amid broad market risk-on sentiment
UroGen Pharma is trading 4.25% up at $49.11, alongside a broader risk-on session. - The Nasdaq Composite is up 0.66%, while the S&P 500 is up 0.33%. - No new...
🟢 UroGen Pharma is trading 4.4% up today after Q2 revenue beat
UroGen Pharma is trading 4.41% up now at $47.49 as investors continued reacting to August 5 earnings showing second-quarter revenue of $72.5 million, above the...
UroGen Pharma's second quarter revenue nearly triples to $72.5 million, driven by strong ZUSDURI launch.
UroGen Pharma reported second quarter revenue of $72.5 million, a significant increase from $24.2 million in the prior-year period. The company posted a net...